Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Article English OPEN
Pouessel , Damien; Chevret , Sylvie; Rolland , Frédéric; Gravis , Gwenaëlle; Geoffrois , Lionel; Roubaud , Guilhem; Terrisse , Safae; Boyle , Helen; Chevreau , Christine; Dauba , Jérôme; Moriceau , Guillaume; Alexandre , Ingrid; Deplanque , Gaël; Chapelle , Angélique; Vauleon , Elodie; Colau , Alexandre; Audenet , François; Grellety , Thomas; Culine , Stephane;
(2016)
  • Publisher: Elsevier
  • Identifiers: doi: 10.1016/j.ejca.2015.11.017
  • Subject: Neoadjuvant chemotherapy | [ SDV ] Life Sciences [q-bio] | Urothelial carcinoma | Muscle-invasive disease | [SDV]Life Sciences [q-bio] | Dose intensity | Transitional cell carcinoma

International audience; Background There is continuing controversy regarding the optimal regimen for neoadjuvant chemotherapy (NAC) in bladder cancer. Patients and methods We performed a retrospective analysis of 241 consecutive bladder cancer patients who received a co... View more
Share - Bookmark